top of page

Our Team

TImo Schmidt.png

Dr. Timo Schmidt

Founder and CEO

Industrial pharmacist (DE) and PhD (CH). Timo brings over 25 years of experience as manager in international pharmaceutical companies and consulting. He is responsible for (or has made significant contribution to) the successful development of many value-generating and IP-protected medicinal products. Furthermore, he has scaled up and lead international companies operating and researching under GMP.

Annike Schroer.png

Annika Schroer

Business Development 

Industrial pharmacist and postgraduate Master of Drug Regulatory Affairs (DE).

Annika brings over 20 years of experience in international pharma corporations. She worked in different roles and was initially responsible for the development and approval of generic drugs. For the past 15 years she has built a distinguished track record in international business development.

Georg Tölkhaus.png

Georg Toelkhaus, CFA

CFO 

Georg worked for many years in various roles for „Big4" firms, in corporate M&A and strategic controlling for a global satellite operator as well as investment banking advisory. In 2021 he became Partner and CFO at Steiger Venture Partners AG. Furthermore, he gained experience as CFO at an AI-startup.

Georg qualified as Swiss Certified Public Accountant in 2010. In 2014 he obtained the prestigious CFA charterholder designation.

Thomas Kerscher.png
Peter Huber.png
Ludger Spitz.png

Dr. Thomas Kerscher

Member of the Board

Dr. Kerscher studied chemistry at the LMU Munich and holds a doctorate in pharmacy.

 

His professional career includes senior positions at global companies such as Procter & Gamble Pharmaceuticals Germany, Novartis Pharma AG and Takeda Pharma, where he was Head of Marketing, Global Brand Director and Business Unit Leader Immunology & Respiratory.

 

Until the end of 2023, Dr. Kerscher held the position of CEO Europe at Aspen Pharma. His focus is on the development and implementation of business models, strategies and financing concepts.

Dr. Peter Huber

Advisory Board

Dr. Huber holds a doctorate in natural sciences (ETH) and an Executive MBA (HSG).

He has many years of experience in various international functions in the pharmaceutical industry. During his career, he was a member of the Executive Board at Spirig Pharma AG; Managing Director at Intergenerika (manufacturers' and distributors' association of generics/ biosimilars in Switzerland) and Head of Swiss Public & Economic Affairs, Novartis International AG.

Since 2023, he has been Chairman of Helvecura Genossenschaft and a member of the Board of Directors of Hemex AG.

Ludger Spitz

Advisory Board

Ludger Spitz worked for over five years as International Senior Product Manager at Vifor Pharma AG, where he developed the global brand concept in cardiology and nephrology. Previous positions include Global Brand Manager Transplantation at Novartis and Senior Product Manager HIV/Virology at Bristol-Myers Squibb.

With extensive experience in strategic brand planning and leading interdisciplinary teams,  Ludger has built an impressive track record in the pharmaceutical industry. Oractive also greatly benefits from his in-depth medical expertise.

Our Memberships

image.png
SBA-Logo-Member.png
2021-swiss-hlg-logo-black.png
bottom of page